GLP1R and type 2 diabetes mellitus: For this aim, two matched groups of 54 participants, naïve to GLP-1 RAs, who were prescribed DU 1.5 mg/once weekly or LIRA 1.2–1.8 mg/once daily as add-on therapy to MET or a combination of MET plus conventional insulin secretagogues, for a minimum of 18 months, were selected, controlling for age, gender, T2D duration, degree of glycemic impairment, cardiovascular comorbidities, and background medications.